Novartis gains global rights to an Arvinas protein degrading drug that targets the androgen receptor to treat prostate cancer. The deal also includes a preclinical molecule addressing an androgen receptor variant.
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Pfizer is paying big bucks for yet-to-be-discovered small molecule drugs that can break down harmful proteins in diseases such as cancer and Alzheimer’s.
Yale spinout Arvinas just raised $41.6 million for its platform of protein degradation drugs - a different mechanism than the standard protein inhibition drugs on the market.